Updated with additional information.
SAN DIEGO (
for $230 million to bolster its pipeline of experimental hepatitis C drugs, the company said Monday.
Anadys shareholder will receive $3.70 per share in cash from Roche, which represents a 256% premium over Anadys' closing price of $1.04 per share on Friday.
By acquiring Anadys, Roche hopes to develop safer, convenient and all-oral treatments for hepatitis C that do not the use of injectable interferon -- a goal shared by all of the major drug makers pursuing new hepatitis C therapies.
Anadys' most advanced hepatitis C drug candidate is a pill known as setrobuvir. Results from a
mid-stage study testing setrobuvir
in combination with injectable interferon and ribavirin, another oral hepatitic C medicine, were announced last Thursday.
On a conference call Thursday, Anadys' executives insisted that the phase II results demonstrated setrobuvir's potential to be part of a future combination therapy against hepatitis C. Yet Anadys' share price barely moved after the setrobuvir data were released last week, suggesting investors took a dimmer view of the drug's prospects.
Other small, independent hepatitis C drug makers may react in sympathy Monday as investors anticipate more deal-making activity in hepatitis C.
are all developing hepatitis C drugs that could potentially be a part of an all-oral, interferon-free regimen being pursued by larger drug companies such as
Johnson & Johnson
is the best-performing biotech stock this year due to the excitement over its hepatitis C drug candidates. Yet the Anadys acquisition may be perceived as a negative given Roche's existing hepatitis C partnership with Pharmasset. Investors will inevitably ask why Roche didn't acquire Pharmasset, although with a current market value of almost $6 billion, Roche may have deemed Pharmasset to be too expensive.
In addition to setrobuvir, Roche's portfolio of hepatitis C drugs includes danoprevir, which it acquired from InterMune last year; RG7128 (the drug partnered with Pharmasset); and wholly owned RG7432. Roche, of course, also sells the Pegasys, the market-leading interferon.
The Anadys deal may also up the pressure on existing hepatitis C powerhouse
(VRTX - Get Report)
to seek out new deals to develop an all-oral therapy. The commercial launch of Vertex's new, powerful hepatitis C drug Incivek has been a success but the drug must be combined with interferon and ribavrin. Vertex has a next generation hepatitis C drug, VX-222, in clinical testing but has not yet been able to find a way to make that drug work without the need for interferon.
--Written by Adam Feuerstein in Boston.
>To contact the writer of this article, click here:
>To follow the writer on Twitter, go to
>To submit a news tip, send an email to:
and become a fan on